Lilly pulling Lartruvo after failure in confirmatory study

Following the failure in January of Lartruvo olaratumab to show a survival benefit in a confirmatory study, Lilly now intends to withdraw the drug from the market. Since 2016, Lartruvo has been approved to treat soft tissue sarcoma under FDA's accelerated approval and EMA's conditional approval pathways.

Eli Lilly and Co. (NYSE:LLY) said in January that the Phase III ANNOUNCE trial of Lartruvo did not meet its primary endpoint. Given in combination with doxorubicin, Lartruvo failed to show an overall survival (OS) benefit vs. doxorubicin alone in either the full study population or a subpopulation of patients with leiomyosarcoma (see "Lartruvo Fails Confirmatory Study; Lilly Suspending Promotion")...